puls delay may hamper share initi believ street
focus puls time rais price target
maintain buy rate rais pt
follow result deliv impress top-lin growth
y/i sale driven us spinal hardwar growth solid
y/i growth nuva later single-posit surgic
product demonstr abil take share improv effici
sizabl impact us spinal hardwar growth believ room
run push train surgeon management estim
custom base train current big question come tonight around
guidanc pre-announce earli januari consensu top-lin
growth impli ahead call essenti bracket overal top-
line revenu growth call top-lin driven us spinal
hardwar us surgic support
surpris around puls time though management note valid work
requir essenti push back commerci later bulk
analyst question around puls time bluntli believ street
overli focus puls come market think expect puls
carri much weight share sinc time origin delay
nass last year much nuva share appreci strength us hardwar
backdrop stabl spine market puls view offer upsid
long us hardwar continu current rate dont believ investor worri
puls ultim market robot spine still earli
penetr move slower initi investor expect
entrench player buy pt globu medic
neutral view undoubtedli bit transit year
given invest prepar euromdr new product launch
constrain om near-term said would use weak
reaction puls time add posit
investor see puls management note puls beta
intend continu iter puls like push time robot
later import rememb puls platform key
compon readi market earlier like
robot compon could still provid revenu prior launch
robot arm clinic feedback encourag puls
us surgic support guidanc put take management clear us
surgic support benefit nc bill collect
come guidanc slowdown
driven dynam increas price pressur biolog
price pressur iom busi collect like take quarter
normal get lsd growth across us surgic support line
addit invest expect limit management articul plan
invest ahead euromdr new surgeon educ facil manufactur
op collect guidanc call vs
valuat rate buy pt base base split
valuat price-to-earnings ev/ebitda respect risk
discuss
idc btig estim compani document
million except per share amount
grown market rate innov product offer organ acquir
undergon transform focus improv oper profit also provid health
system partner rather sole act implant vendor new management come reset
expect also balanc margin expans see opportun upsid top-lin puls
puls robot us hardwar continu outperform us spine market
lap carrolton invest
expect commerci puls
expect commerci puls robot
base case assum result in-lin nuva guidanc specif
assum us hardwar growth us surgic support growth
growth xfx ep expect fall within
rang
see multipl lever upsid base case scenario could lead
rapid growth primarili rapid growth puls system
believ beyond return improv result
biolog nc could boost us surgic support new product introduct
cervic open spine surgeri consid
downsid base case would like driven lack execut
new product increas competit worse-than-expect price pressur
procedur slowdown margin slower worse-than-expect
improv manufactur oper improv would add
global leader spinal
solut largest pure play
instrument servic base
compani market today
transform
integr solut compani
introduct integr
global align platform
focus spinal align
nuvas offer product
solut numer spinal
condit complex spinal
deform degen spinal
report result overal revenu y/i btig consensu
expect y/i y/i respect segment report spinal
hardwar surgic support includ puerto rico revenu
y/i y/i xfx versu expect y/i y/i
y/i respect gross margin came bp estim sg
percentag revenu slightli estim slightli
estim told adjust ep quarter beat btig consensu estim
made follow chang model
revenu mix increas expect revenu growth beyond us spinal hardwar
estim low given improv result see believ us hardwar growth
trend higher off-set previous bullish expect us surgic support lower
meaning match us surgic support guidanc one-tim benefit saw collect bill
within nc back estim off-set slight improv biolog busi growth
level came previou expect collect still increas us hardwar
busi drive meaning growth also built preliminari estim
actualsbtig estimate varianceu spinal hardwar bpsu surgic support growth bpstotal growth net gross margin bpsadj sg bpsr spend bpsadj ebit margin bpstax bpssourc btig research estim compani filingsvari
 tweak gm expect slight improv beyond also increas
expect step-up spend associ sg increas tax rate slightli
adjust share-count match management commentari
rate buy pt previous base split valuat price-to-earnings ev/ebitda
price-to-earnings basi use month ep estim ev/ebitda basi use month ebitda
estim give slight discount peer given lower growth profil rel compar compani
increas multipl show consist top-lin execut risk rate pt includ
competit slowdown spine procedur product develop timelin oper execut manufactur
product challeng intern slow subsequ recoveri acquisit fail improv growth
net ebit btig research estim compani filingsnewold chang
incom etot y/i sale time oper incom expens incom tax expens net incom share net incom share net net oper expens btig research estim compani report
revenu eu spinal hardwar surgic support includ includ growthu spinal hardwar surgic support includ includ growthu spinal hardwar surgic support includ includ splitu spinal hardwar surgic support includ btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
